3rd Innovations in Drug Formulation and Delivery
Start
Wed, 20 May 2015, 00:00
End
Thu, 21 May 2015, 00:00
Venue:
KEYNOTE SPEAKERS
Exhibit
Symposia
Workshops
Organiser
Sponsor
The 3rd Annual Innovations in Drug Formulation and Delivery
Developers of both small- and large-molecule therapeutics urgently need to overcome drug formulation and delivery challenges in order to improve bioavailability and therapeutic performance. Small molecule drugs are challenged by poor solubility, and while enabled formulations can help with this, they often encounter stability hurdles of their own. Intravenous delivery of biologics sets limits on patient adherence and market success, so the next generation of delivery challenges will focus on subcutaneous and oral routes to broaden product pipelines and lengthen life cycles.Registration & Fees
Pricing information for 3rd Annual Innovations in Drug Formulation & Delivery
EARLY BIRD RATE — Register by April 3, 2015
Price
Conference Only $1,795
Conference and Workshop $2,095
Standard Rate
Conference Only $1,995
Conference and Workshop $2,295
Onsite Rate
Conference Only $2,095
Conference and Workshop $2,395
*Includes Sales Tax and Service Fees
Payment:
Make checks payable to ExL Events, Inc. and write code C618 on your check. You may also use Visa, MasterCard, Discover or American Express. Payments must be received in full by the conference date. Any discount applied cannot be combined with any other offer‚ and must be paid in full at the time of order. Parties must be employed by the same organization and register simultaneously to realize group discount pricing options. Group discounts available to individuals must be registered simultaneously and employed by the same organization.**Please note, there will be an administrative charge of $300 to substitute, exchange and/or replace attendance badges with a colleague occurring within five business days of any ExL conference.**
Click here to register.
Maximize Stability and Life Cycle Access for Subcutaneous Biologic Formulations
- Reviewing the parameters that define the outcome of subcutaneous biologics in man
- Studying the interplay between excipients that add shelf life stability and those that reduce pain at the site of injection
- Examining the lineup of sugars, surfactants, amino acids and other non-physiologic excipients that prevent oxidation and deamidation
- Demonstrating the mechanism by which pH changes destroy or sap potency from injected proteins
- Installing rationally designed testing regimens to determine the utility of excipients that keep biologics nearer to immediate injection site or slow down rate of release
- Foreseeing implications for the transition from IV to subcutaneous delivery to oral delivery